Parkinson’s disease (PD) is a neurodegenerative disorder that affects predominantly dopamine-producing (“dopaminergic”) neurons in a specific area of the brain called substantia nigra.

Participate

There are currently several studies for Parkinson’s taking place at the clinic. Please contact the coordinators of these studies by filling in the form below.








Neurogym and Clinical Research

Until recently, there were few, if any, evidence-based neurological treatments beyond that of the pharmacological variety. This is changing. Thanks to our NeuroGym, we now offer neuro-physiotherapy and custom-designed training equipment to complement pharmacological approaches.

The notion that specific physical exercises can help slow disease progression and speed up recovery, though often intuitively applied in other fields, is nonetheless novel to neurology. This gives us the opportunity to conduct cutting-edge evidence-based research concerning the efficacy of combined treatment options. Best of all, it also gives patients the opportunity to take charge of their recovery. Click here to find out more about NeuroGym.

In accordance with our mandate to provide the most comprehensive neurological care possible, we were the first to introduce Transcranial Magnetic Stimulation (“Mag-Stim“) to the Gatineau region. Mag-Stim’s efficacy in treating neurological issues is now well documented, and its use is no longer uncommon in the Ottawa-Gatineau region’s psychiatric centers. Click here to find out more about Magnetic Stimulation.

That being said, we continue to be at the forefront of this treatment’s evolution; consistently developing new and better protocols thanks to our Neuro-Navigation, which allows us to actively and accurately plot the areas of the brain we stimulate with greater precision. Like every other neurological tool at Clinique Neuro-Outaouais, this allows us to not only research better treatments but also to provide a new level of customized care.

The Future

In the short term, it is our ability to combine treatments that provide the most avenue for increased efficacy; a complement to ongoing clinical research which promises gradual long-term improvement.

At Clinique Neuro-Outaouais, we’re excited to have had evidence-based success in improving patient care. We invite you to read our blog, and to contact us in order to learn more about our ongoing research trials and the range of our services.

.

Symptoms & Cause

Symptoms generally develop slowly over years. The progression of symptoms is often a bit different from one person to another due to the diversity of the disease. People with PD may experience:
Tremor, mainly at rest and described as pill-rolling tremor in hands. Other forms of tremor are possible
-Bradykinesia
-Limb rigidity
-Gait and balance problems

The cause remains largely unknown. Although there is no cure, treatment options vary and include medications and surgery. While Parkinson’s itself is not fatal, disease complications can be serious.

Diagnose & Treatment

There is no “one way” to diagnose Parkinson’s disease (PD). However, there are various symptoms and diagnostic tests used in combination. Making an accurate diagnosis of Parkinson’s — particularly in its early stages — is difficult.
There is no standard treatment for Parkinson’s disease (PD). Treatment for each person with Parkinson’s is based on his or her symptoms. Treatments can include medications, physical therapy, surgical options, medical marijuana, clinical trials, lifestyle modifications, like getting more rest and exercise.
There are many medications available to treat Parkinson’s symptoms, although none yet that reverse the effects of the disease. It is common for people with PD to take a variety of these medications — all at different doses and at different times of day — to manage symptoms.

Importance of clinical research

Scientists and doctors are working together to find a treatment or prevention technique.
The clinical research will help to attract the attention of the federal and state government as well as the pharmaceutical industry to the growing need and urgency in addressing PD. This is an important first step to better understanding who develops PD and why.

We participate in a number of clinical trials aiming to create advancements for the treatment of Multiple Sclerosis, Stroke, Parkinson’s, Alzheimer’s and Glioblastoma Multiforme (GBM). Our participation allows us to offer many treatments long before they become available to a majority of specialists, giving patients an opportunity to choose from a wide range of care that, while experimental in nature, may possibly be more effective.

Cutting edge treatments aren’t the only reason we conduct clinical trials, nor are they the only reason patients decide to participate. Our involvement gives us the opportunity to develop better protocols and, most importantly, to help advance the treatments themselves.

When it comes to Neurological diseases, large strides have been made in recent years; results that would have been impossible without the participation of Doctors, Nurses and, most of all, patients.